Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

NDA FilingXPOVIORuxolitinibPositive

AI Analysis

Summary

Karyopharm submitted a Supplemental New Drug Application to the FDA for XPOVIO (selinexor) in combination with ruxolitinib for the treatment of myelofibrosis patients.

Outcome Details

Supplemental New Drug Application submitted

Importance:6/10

Sentiment:

0.50

FDA submissionmyelofibrosiscombination therapyselinexorruxolitinib

Related Companies

$KPTI

Read the original article

Published by yahoo_finance on August 31, 2026 11:30 AM

Read Original